EULAR Highlights 2017

FRI0252
FRI0253
FRI0254
FRI0313
FRI0321
FRI0336
FRI0673
Saturday June 17, 2016
POSTERS
SAT0026
SAT0083
SAT0170
SAT0181
SAT0182
SAT0183
SAT0184
SAT0189
SAT0192
SAT0193
SAT0194
Summary of Neutropenia in Patients with Rheumatoid Arthritis Treated
with Sirukumab in the SIRROUND Phase 3 Clinical Trials
Patient-Reported Outcomes in Patients with Rheumatoid Arthritis
Treated with Subcutaneous Tocilizumab Compared with Placebo or
Intravenous Tocilizumab in Combination with csDMARDs
Efficacy of Tocilizumab for Suppressing Radiographic Progression of
Cervical Lesions in Patients with Rheumatoid Arthritis Comparison
with Methotrexate Treatment; Two Years of Follow-Up ~A Multicenter
Registry Study ~
The Efficacy and Safety of Tocilizumab Therapy in Patients With
Polymyalgia Rheumatica who were Resistant or Intolerant to
Glucocorticoids and Additional Methotrexate
Circulating Il-6 and Other Metabolic Biomarkers Comparing Effects
of Modified-Release Prednisone (MR) and Immediate-Release
Prednisolone (IR) in new GCA
Efficacy of Tocilizumab in 31 Patients with Giant Cell Arteritis
Clinical Remission in Tocilizumab-Using Rheumatoid Arthritis Patients
can be Overestimated: A Cross Sectional Study Using Ultrasound
Sonography
Signalling Through Insulin-Like Growth Factor 1 Receptor Contributes
to IL-6 Production and Supports T Cell Dependent Inflammation in
Rheumatoid Arthritis
Tocilizumab Induced Clinical Remission in Rheumatoid Arthritis had
More Residual Doppler Signals in Comparison With Other Biologics
B-Cell Phenotype and IGD-CD27- Memory B Cells are Affected by TNF-
Inhibitors and Tocilizumab Treatment in Rheumatoid Arthritis
Low Dose Interleukin-2 Combined with Tocilizumab Selectively
Increases Regulatory T Cells Helping Refractory Rheumatoid Arthritis
Patients Achieve Remission More Rapidly
Sirukumab Leads to Significant and Clinically Meaningful Improvements
in Health-Related Quality of Life That Meet or Exceed Normative Values
in Patients With Rheumatoid Arthritis Refractory to TNF Inhibitors in Post
Hoc Analyses of a Phase 3 Trial
Clinical Remission in Subjects With Rheumatoid Arthritis Treated With
Subcutaneous Tocilizumab as Monotherapy or in Combination With
Methotrexate Or Other Synthetic Dmards: A Real-World Clinical Trial
(TOSPACE)
Therapeutic Drug Monitoring on Rheumatoid Arthritis Patients With
Reduced Doses of Intravenous Tocilizumab
Factors Influencing the Prescription of Tocilizumab Alone or in
Combination With DMARDs in Rheumatoid Arthritis Patients in a Real
Life Setting. Pooled Analysis of 3 Observational Studies
Sarilumab Suppresses Thrombosis-Related Gene Expression in
Circulating Blood Cells in MTX-IR and TNF-IR Patients With Active
Rheumatoid Arthritis
RA Patients With Inflammatory Anemia Benefit From Increased
Hemoglobin and Decreased Fatigue Under Tocilizumab Therapy
Sirukumab Integrated Safety in Rheumatoid Arthritis Patients: Analysis
of the SIRROUND Phase 3 Data
SAT0198 Tocilizumab for the Management of Rheumatoid Arthritis:
Discontinuation Due to Inefficacy and Toxicity – Experience from a Large
Teaching Hospital
SAT0199 Subcutaneous Tocilizumab Monotherapy or Combined With a csDMARD
in Patients With Rheumatoid Arthritis: Tozura, a Pooled Analysis of Phase
IV Studies In 22 Countries
SAT0202 Efficacy and Safety of Sarilumab Monotherapy Versus Adalimumab
Monotherapy in Patients With Active Rheumatoid Arthritis in the Phase 3
Monarch Study, Including Subpopulations
SAT0203 Significance of Extension of Tocilizumab Infusion Intervals From 4
Weeks to 6 Weeks in RA Patients Who Had Shown Good Response to 4
Week Intervals
SAT0206 Retention of Tocilizumab as Monotherapy Versus TNF Inhibitors With
Conventional Synthetic DMARDs in Rheumatoid Arthritis Patients With
Inadequate Response to TNF Inhibitors: A Study From The TOCERRA
Collaboration
SAT0209 Observational Study on the Effects of IL-6 Inhibitor Therapy on Myostatin
in Patients With Rheumatoid Arthritis
SAT0212 Sarilumab Dose Reduction in an Open-Label Extension Study in RA
Patients With Inadequate Response to TNF Inhibitors
SAT0214 An Analysis of Increasing Spacing Time for the Intravenous
Administration of Tocilizumab in Patients With Rheumatoid Arthritis
SAT0218 Effect of Tocilizumab in DMARD-Naïve Early Rheumatoid Arthritis Patients
on Health-Related Quality Of Life: Results of the U-ACT-Early Trial
SAT0524 Utility of Tocilizumab in Clinical Manifestations of Erosive Osteoarthrosis
of Hands
Regional Hospital ISSTE Puebla, México
Chairman’s picks